Business

Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets

Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets

articleSinotherapeutics, Inc. Class AMay 12, 20254/news/announcement-on-voluntary-disclosure-of-obtaining-us-fda-approval-number-for-the-companys-dapagliflozin-and-metformin-hydrochloride-sustained-release-tablets
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets

About this update from Sinotherapeutics, Inc. Class A

Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release TabletsThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sinotherapeutics, Inc. Class A